TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)
September 17, 2024 5:54 AM EDTPiper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $11.00 price target on Sutro Biopharma (NASDAQ: STRO).
The analyst comments "At ESMO, initial Phase I/II data on 4.3mg/kg q3W luvelta in combination with Avastin (bevacizumab) achieved impressive 56% (5/9) ORR in late-stage... More
